Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2017; 7(6): 197-201


The Increased Expressions of Type IV Collagen in Cochlear Fibroblasts of Diabetic Rat Models Caused by Curcumin Therapy

Tengku Siti Hajar Haryuna, Farhat Farhat, Faathir Agung Ainul Taufika, Juliandi Harahap, Lidya Imelda Laksmi, Wayan Suardana.




Abstract

Damage to fibroblasts within the cochlear lateral wall is suggested as one of the causes of hearing loss in patients with diabetes mellitus. The aim of this study was to prove curcumin as a safe and effective substance to treat the fibroblasts damage measured by the expressions of type IV collagen. Twenty-four Rattus norvegicus were randomly divided into 6 groups (n=4). Group I: the control group; group II: the diabetic group; group III and IV: the diabetic groups received curcumin therapy 200 and 400 mg/kgBW/day from day 3 - 5; group V and VI: the diabetic groups received curcumin therapy 200 and 400 mg/kgBW/day from day 3 - 10. Curcumin [16.62 ± 0.14]% w/w compared to Standard was administered orally, derived from Curcuma longa Linnaeus (turmeric). All samples were immunohistochemistrically examined for the expressions of type IV collagen in cochlear fibroblasts. Statistically significant differences were found for the expressions of type IV collagen (p

Key words: Diabetes mellitus, curcumin, type IV collagen, fibroblast, cochlea






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.